Keryx Biopharmaceuticals
Boston
About Keryx Biopharmaceuticals
Keryx Biopharmaceuticals is a biopharmaceutical company that is focused on the development and commercialization of medicines for chronic kidney diseases. Keryx Biopharmaceuticals offers Auryxia, a medicine that is able to lower the amount of phosphate in blood. It supports investigator sponsored research conducted by independent researchers with Auryxia. It facilitates programs such as Reimbursement Help, Copay Program, and Patient Assistance. Keryx Biopharmaceuticals was founded in October 1998 and is based in New York.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Estimated revenue: $10K – $50K
- Total funding: $110.0M
- Funding stage: M&A
- Last round: Post-IPO Equity (Jan 2015)
- Ticker: nasdaq:KERX
- Website: keryx.com
- Phone: +1 212-531-5965
Industries & Categories
Biotechnology, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/keryx-biopharmaceuticals-3246643 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.